Treating psoriatic arthritis: How effective are TNF antagonists?

Arthritis Research and Therapy

Volumn 6, Issue SUPPL. 2, 2004, Pages

  Gottlieb, Alice B ^a   Antoni, Christian E ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Arthritis; Etanercept; Infliximab; Psoriasis; Spondyloarthropathies; Tumor necrosis factor

Indexed keywords

AZATHIOPRINE; ETANERCEPT; GOLD SALT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; JOINT DESTRUCTION; PSORIATIC ARTHRITIS; REVIEW; SYNOVIAL FLUID; DRUG ANTAGONISM;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044477587     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1016     Document Type: Review

References (32)

1. Koo JY: Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999, 26:723-733.
2. Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46:1-23.
3. Gladman DD: Psoriatic arthritis. Rheum Dis Clin North Am 1998, 24:829-844.
4. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000, 27:1247-1250.
5. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK: Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987, 62:127-141.
6. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ: Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994, 33:834-839.
7. Gladman DD, Anhorn KA, Schachter RK, Mervart H: HLA antigens in psoriatic arthritis. J Rheumatol 1986, 13:586-592.
8. Gladman DD, Farewell VT: The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995, 38:845-850.
9. Eastmond CJ: Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol 1994, 8:263-276.
10. Prinz JC: Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001, 26:326-332.
11. Costello P, Bresnihan B, O'Farrelly C, FitzGerald O: Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999, 26:1117-1124.
12. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS: Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997, 24:518-523.
13. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544-1552.
14. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002, 46:850-860.
15. Gladman DD, Rahman P: Psoriatric arthritis. In Kelly's Textbook of Rheumatology. Edited by Ruddy S, Harris ED Jr, Sledge CB. Philadelphia: WB Saunders Company; 2001:1071-1079.
16. Jackson CG: Immunomodulating drugs in the management of psoriatic arthritis. Am J Clin Dermatol 2001, 2:367-375.
17. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, McCune WJ: Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995, 22: 894-898.
18. Perlman SG, Gerber LH, Roberts RM, Nigra TP, Barth WF: Photochemotherapy and psoriatic arthritis. A prospective study. Ann Intern Med 1979, 91:717-722.
19. Mahrle G, Schulze HJ, Brautigam M, Mischer P, Schopf R, Jung EG, Weidinger G, Farber L: Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol 1996, 135:752-757.
20. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, Cantini F, Salaffi F, Padula A, Lovino C, Dovigo L, Bordin G, Davoli C, Pasero G, Alberighi OD: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001, 28:2274-2282.
21. Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, Dijkmans BA, Vaishnaw AK, Bos JD, Tak PP: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776-2784.
22. Mader R, Gladman DD, Long J, Gough J, Farewell VT: Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med 1995, 18:139-143.
23. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241-245.
24. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.
25. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
26. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
27. Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®): results of a phase 3 multicenter clinical trial. Arthritis Rheum 2001, 44 (Suppl 1):13-14.
28. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602.
29. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002, 46:755-765.
30. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E: Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002, 22:227-232.
31. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002, 47:506-512.
32. Antoni C, Kavanaugh A, Kirkham B, Burmester G, Weisman M, Keystone E, Ebner W, Furst D, Wassenberg S, Grunke M, Schneider U, Tutuncu Z, Kalden J, Smolen J: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Presented at the 66th/37th Annual Scientific Meeting of the ACR/ARHP held in New Orleans, Louisiana, 24-29 October 2002. Clinical Research Center UMDNJ-RWJ Medical School, New Brunswick, NJ, USA